205 related articles for article (PubMed ID: 31142708)
1. [Current status and future prospect of enzyme replacement therapy for Fabry disease].
Ohashi T
Rinsho Shinkeigaku; 2019 Jun; 59(6):335-338. PubMed ID: 31142708
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
3. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib RP; Nascimento P; Pastores GM
Cochrane Database Syst Rev; 2013 Feb; (2):CD006663. PubMed ID: 23450571
[TBL] [Abstract][Full Text] [Related]
5. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
6. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
7. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
Hughes DA; Nicholls K; Sunder-Plassmann G; Jovanovic A; Feldt-Rasmussen U; Schiffmann R; Giugliani R; Jain V; Viereck C; Castelli JP; Skuban N; Barth JA; Bichet DG
Am J Med Genet A; 2019 Jun; 179(6):1069-1073. PubMed ID: 30920142
[No Abstract] [Full Text] [Related]
8. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data.
Riccio E; Zanfardino M; Ferreri L; Santoro C; Cocozza S; Capuano I; Imbriaco M; Feriozzi S; Pisani A;
Eur J Hum Genet; 2020 Dec; 28(12):1662-1668. PubMed ID: 32647377
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of Fabry disease: Successes, failures, and expectations].
Lidove O; Barbey F; Joly D
Nephrol Ther; 2016 Apr; 12 Suppl 1():S105-13. PubMed ID: 26968478
[TBL] [Abstract][Full Text] [Related]
10. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Mac Lochlainn DJ; McKechnie DGJ; Mehta AB; Hughes DA
Mol Genet Metab; 2018 Feb; 123(2):154-158. PubMed ID: 29055531
[TBL] [Abstract][Full Text] [Related]
11. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib RP; Pastores GM
Cochrane Database Syst Rev; 2010 May; (5):CD006663. PubMed ID: 20464743
[TBL] [Abstract][Full Text] [Related]
13. Developments in the treatment of Fabry disease.
van der Veen SJ; Hollak CEM; van Kuilenburg ABP; Langeveld M
J Inherit Metab Dis; 2020 Sep; 43(5):908-921. PubMed ID: 32083331
[TBL] [Abstract][Full Text] [Related]
14. Progressive renal failure despite long-term biweekly enzyme replacement therapy in a patient with Fabry disease secondary to a new α-galactosidase mutation of Leu311Arg (L311R).
Suzuki K; Miura N; Kitagawa W; Suzuki S; Komatsuda A; Nishikawa K; Watanabe D; Imai H
Clin Exp Nephrol; 2011 Dec; 15(6):916-20. PubMed ID: 21755431
[TBL] [Abstract][Full Text] [Related]
15. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
Pisani A; Riccio E; Sabbatini M
Genet Med; 2015 Jan; 17(1):21-3. PubMed ID: 25010055
[No Abstract] [Full Text] [Related]
16. Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha.
Reidt S; Namdar M; Serra A; Krayenbühl PA; Gruner C; Keller DI; Lüscher TF; Schmied C
Intern Med J; 2014 Feb; 44(2):205-7. PubMed ID: 24528819
[No Abstract] [Full Text] [Related]
17. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.
Desnick RJ
Expert Opin Biol Ther; 2004 Jul; 4(7):1167-76. PubMed ID: 15268683
[TBL] [Abstract][Full Text] [Related]
18. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
20. Cellular and tissue distribution of intravenously administered agalsidase alfa.
Murray GJ; Anver MR; Kennedy MA; Quirk JM; Schiffmann R
Mol Genet Metab; 2007 Mar; 90(3):307-12. PubMed ID: 17188539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
